Combination therapy with ixekizumab and tirzepatide bested monotherapy with ixekizumab alone in both psoriatic arthritis and ...

Approximately 20% to 30% of all people who suffer from psoriasis also develop painful inflammation in their joints over time.

AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology ...

A group of researchers from the University of Erlangen-Nuremberg has discovered which immune cells migrate from the skin of ...

On Thursday, Eli Lilly and Co. (NYSE:LLY) revealed topline results from the novel TOGETHER-PsA open-label Phase 3b trial ...

The TOGETHER-PsA study shows that combining ixekizumab with tirzepatide leads to significantly better psoriatic arthritis ...

On Jan. 1, 2026, the price of my medication finally came down — and it will change my life. I have been living with psoriatic arthritis for over 40 years, a condition that I treat with a medication ...

Explore the unique aspects of rheumatoid arthritis in men, including diagnosis, symptoms, complications, and support options ...

Optum notable drugs nearing FDA approval include Anaphylm, Sotyktu, and insulin icodec with decisions expected early 2026.

Topline data were announced from a phase 3b trial evaluating the concomitant use of ixekizumab and tirzepatide in adults with active psoriatic arthritis and obesity.

The Commonwealth Transportation Board at its Jan. 6 meeting in Richmond awarded a $218.9 million contract to Triton ...